Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Lorlatinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.